Chemotherapy plus Ofatumumab at Standard or Mega dose In Chronic lymphoid leukemia (CLL)

Trial Profile

Chemotherapy plus Ofatumumab at Standard or Mega dose In Chronic lymphoid leukemia (CLL)

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Bendamustine; Cyclophosphamide; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms COSMIC
  • Most Recent Events

    • 27 Jun 2017 Status changed from recruiting to completed.
    • 25 Jun 2017 Primary endpoint (Proportion of patients achieving a Complete Response) has not been met, according to the abstract presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top